CSL Limited
(ASX:CSL) says exchange rate movements and one-off costs relating to the acquisition of the Novartis flu vaccine business have limited its profit growth.
The biotech giant recorded profit growth of 5.5 per cent to $US1.38 billion for the full year ended 30 June.
However, that figure fell short of market expectations of $US 1.41 billion.
It was just last week that CSL shares breached the $100 mark, the second time ever in the company’s history.
The board has declared an unfranked dividend of US 66 cents per share.
